Literature DB >> 223756

Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.

P Larochelle, J Genest, O Kuchel, R Boucher, Y Gutkowska, D McKinstry.   

Abstract

Seven patients with essential hypertension and seven patients with hypertension associated with renal artery stenosis received captopril (SQ 14225), an inhibitor of angiotensin I converting enzyme. There was a significant reduction in mean blood pressure, from 176/113 +/- 4/3 mm Hg during the control period to 140/90 +/- 5/3 mm Hg during captopril administration. Five patients received captopril alone and nine patients needed hydrochlorothiazide in addition to control their blood pressure. Captopril produced a significant increase in peripheral plasma renin activity. When measured 12 hours after the administration of captopril the angiotensin I converting enzyme activity was found to be similar to that during the control period even though the blood pressure was at or near normal. These findings indicate that although captopril is an effective antihypertensive agent, its action does not depend only on inhibition of plasma angiotensin I converting enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 223756      PMCID: PMC1704340     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  8 in total

1.  [Radioimmunologic determination of plasma renin activity].

Authors:  J Gutkowska; R Boucher; J Genest
Journal:  Union Med Can       Date:  1977-04

Review 2.  Design of new antihypertensive drugs: potent and specific inhibitors of angiotensin-converting enzyme.

Authors:  D W Cushman; H S Cheung; E F Sabo; M A Ondetti
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

3.  Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.

Authors:  D B Case; S A Atlas; J H Laragh; J E Sealey; P A Sullivan; D N McKinstry
Journal:  Prog Cardiovasc Dis       Date:  1978 Nov-Dec       Impact factor: 8.194

4.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

5.  An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients.

Authors:  H Gavras; H R Brunner; J H Laragh; J E Sealey; I Gavras; R A Vukovich
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

6.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

7.  Accentuated vascular and endocrine response to SQ 20881 in hypertension.

Authors:  G H Williams; N K Hollenberg
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

8.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

  8 in total
  5 in total

1.  Captopril treatment of refractory hypertension in children.

Authors:  L L Chan; J W Balfe; B E Hardy
Journal:  Can Med Assoc J       Date:  1981-02-01       Impact factor: 8.262

2.  New drugs for the treatment of hypertension: where do they fit?

Authors:  T W Wilson; M P Dubois
Journal:  Can Fam Physician       Date:  1987-11       Impact factor: 3.275

3.  Increased angiotensin-converting enzyme in peripheral blood monocytes from patients with sarcoidosis.

Authors:  T Okabe; K Yamagata; M Fujisawa; J Watanabe; F Takaku; J J Lanzillo; B L Fanburg
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

Review 4.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

Review 5.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.